{"result": "(\"entity\"<|>FENILCETONURIA<|>EVENT<|>Fenilcetonuria is a metabolic disorder characterized by high levels of phenylalanine in the blood due to a deficiency in the enzyme phenylalanine hydroxylase (PAH).)\n##\n(\"entity\"<|>PAH<|>ORGANIZATION<|>Phenylalanine hydroxylase (PAH) is the enzyme responsible for converting phenylalanine to tyrosine, and its deficiency leads to phenylketonuria.)\n##\n(\"entity\"<|>BH4<|>ORGANIZATION<|>Tetrahydrobiopterin (BH4) is a coenzyme that assists PAH in the metabolism of phenylalanine.)\n##\n(\"entity\"<|>DHPR<|>ORGANIZATION<|>Dihydropteridine reductase (DHPR) is an enzyme involved in the regeneration of BH4, which is crucial for the metabolism of phenylalanine.)\n##\n(\"entity\"<|>EUROPA<|>GEO<|>Southern Europe is noted for having a higher frequency of the IVS10 mutation related to phenylketonuria.)\n##\n(\"entity\"<|>HYPERPHENYLALANINEMIA<|>EVENT<|>Hyperphenylalaninemia is a biochemical phenotype characterized by elevated levels of phenylalanine in the blood, which can lead to phenylketonuria.)\n##\n(\"entity\"<|>PKU<|>EVENT<|>Phenylketonuria (PKU) is a genetic disorder that results in the accumulation of phenylalanine, leading to severe neurological issues if untreated.)\n##\n(\"entity\"<|>HPA<|>EVENT<|>Benign hyperphenylalaninemia (HPA) is a mild form of hyperphenylalaninemia that does not require dietary treatment.)\n##\n(\"relationship\"<|>FENILCETONURIA<|>PAH<|>Phenylketonuria is caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH)<|>9)\n##\n(\"relationship\"<|>FENILCETONURIA<|>BH4<|>Tetrahydrobiopterin (BH4) is a cofactor necessary for the function of PAH, and its deficiency can lead to hyperphenylalaninemia<|>7)\n##\n(\"relationship\"<|>FENILCETONURIA<|>DHPR<|>Dihydropteridine reductase (DHPR) is involved in the regeneration of BH4, which is crucial for the metabolism of phenylalanine and thus affects PKU<|>6)\n##\n(\"relationship\"<|>EUROPA<|>FENILCETONURIA<|>The IVS10 mutation related to phenylketonuria is most frequently found in Southern Europe<|>5)\n##\n(\"relationship\"<|>HYPERPHENYLALANINEMIA<|>PKU<|>Hyperphenylalaninemia can lead to phenylketonuria if not managed properly<|>8)\n##\n(\"relationship\"<|>HYPERPHENYLALANINEMIA<|>HPA<|>Benign hyperphenylalaninemia (HPA) is a milder form of hyperphenylalaninemia that does not require treatment<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ienen todos\nlos aa excepto el o los que están afectados. Es-\ntos preparados no deben ser utilizados como\núnica fuente proteica en situaciones de des-\ncompensación, ya que se convierten en una\nfuente nitrogenada tóxica.\n\n## 2. Fenilcetonuria\n\n### 2.1. Consideraciones generales\n\nLa hiperfenilalaninemia es un término genérico que\nse otorga a un fenotipo bioquímico en el que existe un\naumento persistente de la concentración plasmática de\nfenilalanina (Phe) causado por trastornos de la hidroxi-\nlación hepática¹. Dichos trastornos pueden implicar\ntanto a la enzima fenilalanin-hidroxilasa (PAH), a su\ncofactor, la coenzima tetrahidrobiopterina (BH4) como\na la dihidropteridinareductasa (DHPR).\n\nLa principal causa de hiperfenilalaninemia es el defec-\nto de actividad de PAH.\n\nLa herencia de esta entidad es autosómica recesiva y\nsu incidencia global es de 1:4000/21195 recién naci-\ndos dependiendo de la zona geográfica².\n\nEl gen PAH está localizado en el cromosoma 12\n(12q22-24), habiéndose descrito hasta el momento\nmás de 400 mutaciones, algunas de ellas mutaciones\nde novo³.\n\nLa mutación más frecuente en el sur de Europa es la\nIVS10.\n\nEl diagnóstico bioquímico se establece mediante la\ndeterminación de niveles plasmáticos de Phe mediante\nespectrometría de masas en tándem (MS/MS) superio-\nres a 120-150 μmol/l y se confirma mediante el estudio\nmutacional.\n\n### 2.2. Clasificación y fenotipo clínico\n\nDebido al gran número de mutaciones, el espectro\nclínico es muy amplio y, en la actualidad, la clasifica-\nción más aceptada es la que tiene en cuenta las con-\ncentraciones plasmáticas de Phe y la tolerancia de Phe.\n\nEn este sentido, podemos clasificar las hiperfenilala-\nninemias/PKU:\n\na. Fenilcetonuria clásica: las concentraciones plas-\nmáticas de Phe al diagnóstico son superiores a\n1200 μmol/l; la tolerancia de Phe es inferior a\n350 mg/día. Suelen ser formas muy severas que\ncursan con retraso mental y motor graves si no\nestán tratadas.\n\nFenilcetonuria moderada: las concentraciones\nplasmáticas de Phe al diagnóstico suelen ser 600-\n1200 μmol/l; la tolerancia de Phe es inferior a\n350-400 mg/día.\n\nFenilcetonuria leve: las concentraciones plasmáti-\ncas de Phe al diagnóstico suelen ser 360- 600\nμmol/l; la tolerancia de Phe suele ser de 400-600\nmg/día.\n\nHiperfenilalaninemia benigna (HPA): las concen-\ntraciones plasmáticas de Phe al diagnóstico sue-\nlen ser 120-360 μmol/l. Es una forma benigna,\nleve y no requiere tratamiento dietético.\n\nb. Hiperfenilalaninemia maligna: son las que afectan\nal sistema de la coenzima tetrahidrobiopterina\n(BH4) y su enzima, la DHPR. Estos pacientes mani-\nfiestan síntomas de afectación neurológica debi-\ndo al déficit de neurotransmisores y no suelen\nresponder al tratamiento dietético.\n\n### 2.3. Tratamiento dietético general\n\nEl tratamiento de la PKU es para toda la vida y se\nbasa en la restricción de alimentos con contenido en\nfenilalanina.\n\nHay que destacar la importancia del buen control\ndietético en el pronóstico de la enfermedad⁴.\n\nActualmente existen nuevas opciones terapéuticas\n(véase en el apartado 2.6).\n\nLas bases del tratamiento dietético son las si-\nguientes:\n\na. Limitar la ingesta de fenilalanina en la dieta, con\nel objetivo de conseguir unos niveles de fenilalani-\nna en sangre inferiores a 6 mg/dl (360 μmol/l).\nComo en muchas ocasiones no se dispone de la\ncantidad de Phe que contiene un determinado\nalimento, se estima la cantidad de Phe mediante\n---\nTema 18. Soporte nutricional en metabolopatías de los aminoácidos... 307\n\nel contenido en proteínas naturales de alto valor biológico (PNAVB)14 (tablas 2 y 3).\nEl manejo de la Phe en la dieta PKU se suele hacer mediante un sistema de porciones o intercambios, lo más común suelen ser porciones de 50 mg, cantidad equivalente a 1 g de PNAVB y facilita mucho la confección de la dieta. Pero en aquellos casos en los que la tolerancia es menor puede interesar usar porc\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}